Segall Bryant & Hamill, LLC Amicus Therapeutics, Inc. Transaction History

Segall Bryant & Hamill, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.89 - $12.48 $1.65 Million - $2.61 Million	-209,196 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.82 - $12.44 $95,558 - $121,053	9,731 Added 4.88%	209,196 $2.42 Million
Q3 2021 Nov 03, 2021	BUY	$8.74 - $11.84 $46,322 - $62,752	5,300 Added 2.73%	199,465 $1.9 Million
Q2 2021 Aug 12, 2021	BUY	$8.71 - $10.72 $97,970 - $120,578	11,248 Added 6.15%	194,165 $1.87 Million
Q1 2021 May 13, 2021	SELL	$9.2 - $23.86 $24,067 - $62,417	-2,616 Reduced 1.41%	182,917 $1.81 Million
Q4 2020 Feb 12, 2021	SELL	$13.47 - $24.89 $46,511 - $85,945	-3,453 Reduced 1.83%	185,533 $4.28 Million
Q3 2020 Nov 13, 2020	BUY	$12.89 - $15.89 $1.77 Million - $2.18 Million	137,233 Added 265.17%	188,986 $2.67 Million
Q2 2020 Aug 14, 2020	BUY	$8.86 - $15.69 $14,025 - $24,837	1,583 Added 3.16%	51,753 $780,000
Q1 2020 May 14, 2020	SELL	$6.63 - $11.16 $37,174 - $62,574	-5,607 Reduced 10.05%	50,170 $463,000
Q4 2019 Feb 11, 2020	SELL	$7.48 - $10.75 $30,914 - $44,429	-4,133 Reduced 6.9%	55,777 $543,000
Q3 2019 Nov 12, 2019	BUY	$8.02 - $13.25 $1,996 - $3,299	249 Added 0.42%	59,910 $480,000
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $2,707 - $3,556	247 Added 0.42%	59,661 $0
Q1 2019 May 15, 2019	BUY	$10.04 - $13.92 $15,943 - $22,104	1,588 Added 2.75%	59,414 $0
Q4 2018 Feb 15, 2019	BUY	$8.38 - $13.44 $132,412 - $212,365	15,801 Added 37.6%	57,826 $553,000
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $394 - $562	-34 Reduced 0.08%	42,025 $0
Q2 2018 Aug 08, 2018	BUY	$13.13 - $17.09 $552,234 - $718,788	42,059 New	42,059 $0

313

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.